VPS9D1

The VPS9D1 locus encodes both a VPS9-domain-containing guanine-nucleotide exchange factor (GEF) protein and an antisense long noncoding RNA (VPS9D1-AS1) with distinct biological functions. The VPS9D1 protein specifically activates Rab22A—but not Rab5A—to drive tubular endosome formation and clathrin-independent endocytic cargo recycling, as demonstrated by rescue with constitutively active Rab22A but not a GEF-dead mutant (PMID:36762583). VPS9D1-AS1 functions as an oncogenic lncRNA that operates through multiple mechanisms: it scaffolds ribosomal protein RPS3 to enhance translation of TGF-β pathway components and ISGs in colorectal cancer (PMID:36458816), stabilizes CDK4 mRNA via HuR binding in hepatocellular carcinoma (PMID:34558987), sponges miRNAs (miR-4739, miR-491-5p, miR-532-3p) to de-repress targets such as MEF2D, GPX1, and HMGA2 (PMID:31918265, PMID:32808668, PMID:31902794), and activates Wnt/β-catenin and MEK/ERK signaling across multiple cancer types (PMID:34659577, PMID:33192510). Antisense oligonucleotide-mediated knockdown of VPS9D1-AS1 triggers MLKL-dependent immunogenic cell death and restores CD8+ T cell-mediated tumor killing, establishing VPS9D1-AS1 as a potential immunotherapy target (PMID:40412657).

1. 2019 Medium

   Establishing VPS9D1-AS1 as a transcriptionally regulated ceRNA: ZEB1-driven expression of VPS9D1-AS1 and its sponging of miR-4739 to de-repress MEF2D provided the first mechanistic framework for this lncRNA's oncogenic activity.

   Evidence Promoter binding assays, luciferase reporters, and knockdown/overexpression rescue in prostate cancer cell lines

   PMID:31918265

   Open questions at the time

   • No biochemical reconstitution of ceRNA stoichiometry
   • Only one cancer type tested
   • No in vivo validation
2. 2020 Medium

   The ceRNA paradigm was extended to additional miRNA–target axes (miR-491-5p/GPX1 in ALL; miR-532-3p/HMGA2 in NSCLC) and a distinct signaling mode (MEK/ERK activation in AML), demonstrating that VPS9D1-AS1 engages different downstream effectors in different malignancies.

   Evidence Luciferase reporters, RNA immunoprecipitation, siRNA knockdown/overexpression, xenograft models across three cancer types

   PMID:31902794 PMID:32808668 PMID:33192510

   Open questions at the time

   • ceRNA mechanisms rely on single-lab luciferase/RIP validation
   • No quantitative assessment of miRNA:lncRNA stoichiometry
   • MEK/ERK link lacks a defined intermediate target
3. 2021 Medium

   Beyond miRNA sponging, VPS9D1-AS1 was shown to operate through protein–RNA scaffolding—binding HuR to stabilize CDK4 mRNA—and to activate Wnt/β-catenin signaling, revealing mechanistic diversity beyond the ceRNA model.

   Evidence RNA immunoprecipitation (VPS9D1-AS1–HuR), CDK4 protein/mRNA stability assays, Wnt pathway agonist rescue experiments in HCC and ESCC cell lines

   PMID:34558987 PMID:34659577

   Open questions at the time

   • HuR–CDK4 mRNA stabilization from single lab without domain mapping
   • Wnt pathway link lacks identification of a direct molecular intermediate
   • Relationship between HuR scaffolding and ceRNA functions unresolved
4. 2022 High

   A ribosome-associated scaffolding mechanism was established: VPS9D1-AS1 binds RPS3 to enhance translation of TGF-β, TGFBR1, and SMAD1/5/9, linking the lncRNA to immune evasion through OAS1-mediated IFNAR1 maintenance and resistance to CD8+ T cell killing.

   Evidence VPS9D1-AS1 knockout, lncRNA–RPS3 binding assays, ribosome association experiments, conditional overexpression mouse model, ASO treatment

   PMID:36458816

   Open questions at the time

   • Structural basis of RPS3 interaction undefined
   • Whether translational enhancement is specific to TGF-β targets or broader is unclear
   • Contribution relative to ceRNA activity not quantified
5. 2023 High

   The VPS9D1 protein itself was functionally characterized as a Rab22A-specific GEF that drives tubular endosome biogenesis and clathrin-independent cargo recycling, distinguishing the protein from its antisense lncRNA.

   Evidence siRNA depletion, constitutively active Rab22A rescue, GEF-dead mutant failure to rescue, cargo trafficking assays and live imaging in HeLa cells

   PMID:36762583

   Open questions at the time

   • In vitro GEF kinetic parameters not reported
   • Structural basis for Rab22A specificity over Rab5A unknown
   • Physiological cargos in non-HeLa cell types not defined
6. 2025 Medium

   Therapeutic targeting of VPS9D1-AS1 was demonstrated: ASO-loaded lipid nanoparticles trigger MLKL-dependent immunogenic cell death, suppress HLA-G, and modulate AXL/GAS6 to sensitize tumors to immunotherapy; exosomal transfer of VPS9D1-AS1 to macrophages induces M2 polarization and drug resistance via GSK-3β ubiquitination and Wnt activation.

   Evidence ASO-LNP knockdown in PDX models, MLKL/ICD assays, exosome transfer and co-IP for NCYM/GSK-3β, macrophage polarization assays, in vivo combination immunotherapy

   PMID:40412657 PMID:41207568

   Open questions at the time

   • MLKL activation mechanism downstream of VPS9D1-AS1 loss not fully resolved
   • Exosomal transfer and NCYM recruitment from single lab
   • In vivo pharmacokinetics and off-target effects of ASO-LNP not characterized

• A unified model integrating VPS9D1 protein GEF activity and VPS9D1-AS1 lncRNA functions is lacking; whether the two gene products are co-regulated or functionally interdependent remains unknown.
• No study has examined cross-regulation between VPS9D1 protein and VPS9D1-AS1
• Structural basis for VPS9D1 Rab22A specificity unresolved
• Relative contribution of ceRNA, HuR scaffolding, and RPS3-mediated translation to oncogenesis not quantified